Opioid Policy Research Collaborative

Research

Researchers at the Institute for Behavioral Health (IBH) have been conducting analyses on various aspects of the opioid crisis since the 1990s—much longer than it’s been in the headlines.

That work is primarily divided into two main areas: prevention and treatment. As IBH Director Constance Horgan says, “We believe that dealing with the opioid crisis requires focusing across the continuum, from prevention all the way through treatment, because the situation is getting worse and we need to be more vigilant in changing the conversation if we want to succeed.”

Research Areas

Community Programs

Community Assessment

  • Evaluation of the Advocates Certified Community Behavioral Health Clinic (CCBHC): The major goal of this project is to conduct an evaluation of the design, implementation, and outcomes of the Advocates CCBHC Expansion Project
    Brandeis Lead Scientist: Gail Strickler
  • Massachusetts Community Health Centers Supporting Opioid Addiction Recovery (MA-SOAR)
    Brandeis Lead Scientist: Mary Brolin
  • Enhancements to a Community Based Recovery Oriented System of Care (ROSC) Project
    Brandeis Lead Scientist: Meelee Kim
  • Building Communities of Recovery
    Brandeis Lead Scientist: Meelee Kim
  • Waltham Safe Schools Healthy Students Coalitions Drug Free Communities Support Program Evaluation
    Brandeis Lead Scientist: Meelee Kim
  • Youth and Young Adults (YAYA) HIV Substance Abuse Evaluation
    Brandeis Lead Scientist: Meelee Kim

Rapid Assessment

  • The Rapid Assessment of Consumer Knowledge (RACK): Provides support to conduct ethnographic studies with people of Hispanic/Latino ethnicity, and examining the role of harm reduction service use among people who use drugs in Lawrence and Lowell. 
    Brandeis Lead Scientist: Traci Green

Engaging Populations and Addressing Disparities

  • Engaging Mothers With IDD and Behavioral Health Conditions in Research
    Brandeis Lead Scientist: Joanne Nicholoson
  • Grandparents Raising Grandchildren: Unplanned Consequences of the Opioid Epidemic
    Brandeis Lead Scientists: Margot Davis and Marji Erickson Warfield
  • Creating a Community with Mothers with Mental Illness Using Opioids
    Brandeis Lead Scientist: Joanne Nicholson
  • Intersecting Research on Opioid Misuse, Addiction, and Disability Services (INROADS)
    Brandeis Lead Scientist: Sharon Reif
  • RIZE Foundation of Massachusetts: Racial disparities and the role of prescriber networks in the development and sustaining of buprenorphine prescribing by waivered physicians for OUD treatment in Massachusetts communities.
    Brandeis Lead Scientist: Peter Kreiner
  • RIZE Massachusetts-Harm Reduction Services. Enabling Health: Evaluating Programs Enhancing Harm Reduction Services in Massachusetts
    Brandeis Lead Scientist: Traci Green

Harm Reduction

Drug Checking

  • Drug Checking Pilot Evaluation: The purpose of this study is to pilot the creation and validation of a data stream for public health surveillance of the drug supply
    Brandeis Lead Scientist: Traci Green
  • Fentanyl Test Strip Pilot Study: This study will test the efficacy of a novel drug-checking intervention to prevent fatal and non-fatal overdose among young adults who use drugs.
    Brandeis Lead Scientist: Traci Green
  • One2One: Engagement to recovery using a police-led novel intervention: This study continues a partnership between Brandeis University investigators and the implementing agency, the Police Assisted Addiction and Recovery Initiative (PAARI) in Massachusetts and Maine by supportive outreach and distribution of fentanyl test strips (FTS) and other recovery tools in order to increase engagement in substance use services among people who use drugs and their friends and family.
    Brandeis Lead Scientist: Mary Jo Larson

Overdose Prevention and Naloxone

  • Intervention to Increase Naloxone Engagement & Distribution in Community Pharmacies: A Four State Randomized Trial (Respond to Prevent): The multi-site study will test the efficacy of an intervention for pharmacist-initiated prescription and distribution of naloxone, an overdose antidote, to improve opioid safety and prevent opioid-involved adverse events.
    Brandeis Lead Scientist: Traci Green
  • Naloxone Needed to Save Bayesian Modeling Study
    Brandeis Lead Scientist: Traci Green
  • Overdose Risk Management and Compensation in the Era of Naloxone: This study will conduct longitudinal analyses examining relationships between naloxone exposure (access to and use of naloxone) and overdose risk behaviors, including risk compensatory behavior.
    Brandeis Lead Scientist: Andrew Kolodny
  • Using a Novel Comprehensive Linked Dataset to Determine Early Predictors of Opioid Overdose
    Brandeis Lead Scientist: Peter Kreiner
  • Opioid Overdose Epidemic Crisis Response – Biosurveillance Projects
    Brandeis Lead Scientist: Meelee Kim

Syringe Access

  • Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality. The goal of this study is to examine the impact of pharmacy-based naloxone and assess barriers and facilitators to proper naloxone dispensing.
    Brandeis Lead Scientist: Traci Green

Law and Policy Evaluation

  • Massachusetts Health Policy Forum on the Opioid Epidemic and the Workforce
    Brandeis Lead Scientist: Constance Horgan
  • Measuring the Impact of New Jersey's New Opioid Laws: Our qualitative and quantitative study evaluates the impact of New Jersey's opioid prescribing rules by comparing opioid prescribing before and after the rules went into effect and by interviewing physicians.
    Brandeis Lead Scientist: Andrew Kolodny
  • MassHEAL - Reducing overdose deaths by 40% (2019-2023): The MassHEAL study will implement and evaluate an intervention targeting overdose fatalities in 16 highly- affected Massachusetts communities via a cluster-randomized parallel group design. The primary study outcome is number of overdose fatalities in the last year of a 3-year intervention period.
    Brandeis Lead Scientists: Dominic Hodgkin, Constance Horgan, and Traci Green
  • Developing Evidence Base for Opioid Drug Policies: a Multilevel Analysis of NHBH
    Brandeis Lead Scientist: Peter Kreiner
  • Prescriptive Authority and Nurse Practitioner Opioid Prescribing Practices
    Brandeis Lead Scientist: Cindy Parks Thomas

Military Health

  • Healthcare utilization and readiness outcomes among soldiers with post-deployment at-risk drinking, by comorbidity clusters.
    Brandeis Lead Scientist: Rachel Sayko Adams

  • Improving Treatments and Outcomes among Soldiers Identified with Severe Alcohol Use after Return from OEF/OIF/ OND Deployment.
    Brandeis Lead Scientist: Rachel Sayko Adams
  • Integrating Signals of Suicide Risk from DoD & VHA Data to Improve Upon Suicide Risk Prevention Strategies for Combat Veterans
    Brandeis Lead Scientist: Rachel Sayko Adams
  • Trajectories of Non-pharmacologic and Opioid Health Services for Pain Management in Association with Military Readiness and Health Outcomes
    Brandeis Lead Scientist: Mary Jo Larson
  • Longitudinal Study of Post-Deployment Complementary and Alternative Medicine Pain Management Using Department of Defense (DoD) and Veterans Affairs (VA) Data
    Brandeis Lead Scientist: Mary Jo Larson
  • Variation in Opioid Prescribing Patterns Among Military Prescribers
    Brandeis Lead Scientist: Mary Jo Larson
  • Association of High-Risk Medications with Health Outcomes and Early Attrition Among Post-Deployment Soldiers with Pain
    Brandeis Lead Scientist: Mary Jo Larson
  • Preventing Prescription Drug Problems: A Pilot Military Opioid Safety Initiative
    Brandeis Lead Scientist: Mary Jo Larson

MOUD and Opioid Use Disorder Treatment Approaches

  • Comparing Medication Maintenance in Comprehensive Community and Pharmacy Settings to Enhance Engagement: This project explores the feasibility and utility of partnering pharmacists with treatment providers to improve treatment workflow and achieve better patient outcomes.
    Brandeis Lead Scientist: Traci Green

  • Piloting a Patient-reported Outcome Measure for for OUD Recovery in a Clinical Setting (Recovery PROM)
    Brandeis Lead Scientists: Sharon Reif and Constance Horgan
  • Racial Disparities and Access to OUD Treatment: The Role of Prescriber Networks in Access to OUD Treatment and Number of Individuals at Risk for OUD in Massachusetts Communities
    Brandeis Lead Scientist: Peter Kreiner
  • Washington Hub & Spoke Opioid Treatment Networks - 2nd Generation Approaches to Improve Medication Treatment for OUD
    Brandeis Lead Scientist: Sharon Reif
  • Hub and Spoke Model to Improve Pharmacotherapy Use for Opioid Addiction and Promote Recovery
    Brandeis Lead Scientist: Sharon Reif
  • Expanding Medication-Assisted Treatment: State Medicaid Technical Assistance Opportunities
    Brandeis Lead Scientist: Cindy Parks Thomas
  • Emergency Department Interventions for Opioid Use Disorder
    Brandeis Lead Scientist: Cindy Parks Thomas
  • Evaluation of the Massachusetts SHIFT-Care Program to Initiate Opioid Use Disorder Treatment in Emergency Departments
    Brandeis Lead Scientist: Cindy Parks Thomas

Pain Management and Prescribing

Pain and Alternative Pain Management

  • Trajectories of Non-pharmacologic and Opioid Health Services for Pain Management in Association with Military Readiness and Health Outcomes
    Brandeis Lead Scientist: Mary Jo Larson
  • Longitudinal Study of Post-Deployment Complementary and Alternative Medicine Pain Management Using Department of Defense (DoD) and Veterans Affairs (VA) Data
    Brandeis Lead Scientist: Mary Jo Larson
  • Variation in Opioid Prescribing Patterns Among Military Prescribers
    Brandeis Lead Scientist: Mary Jo Larson
  • Association of High-Risk Medications with Health Outcomes and Early Attrition Among Post-Deployment Soldiers with Pain
    Brandeis Lead Scientist: Mary Jo Larson
  • Preventing Prescription Drug Problems: A Pilot Military Opioid Safety Initiative
    Brandeis Lead Scientist: Mary Jo Larson

Prescription Drug Monitoring Program

PDMPs and Safer Prescribing

  • MDPH /SAMHSA, Drug Checking Pilot Evaluation: This pilot study will first implement and evaluate a drug checking intervention in partnership with police departments in Massachusetts, and will also develop a real-time data collection network for tracking the anatomy of the illicit drug supply in the state.
    Brandeis Lead Scientist: Traci Green
  • Utilization of the New York State Department of Health Prescription Drug Monitoring Program to Reduce Risky Opioid Prescribing Practices.
    Brandeis Lead Scientist: Andrew Kolodny
  • Massachusetts PMP Data Analysis and Evaluation Assistance Project: The major goal of this is to assist the Massachusetts (MA) PMP in analyzing its prescription drug monitoring program data, with a focus on patterns of and trends in controlled substance prescribing.
    Brandeis Lead Scientist: Gail Strickler
  • Analysis of Prescription Drug Monitoring Program (PDMP) Data Assessing Impact of State Interventions on High Risk Prescribers: FDA-funded evaluation of the impact of an intervention by the New York State Department of Health to reduce risky opioid prescribing practices.
    Brandeis Lead Scientist: Andrew Kolodny
  • Prescription Behavior Surveillance System (PBSS): providing epidemiological analyses of de-identified data from state prescription drug monitoring programs to help target and evaluate interventions aimed at reducing prescription drug abuse and diversion.
    Brandeis Lead Scientist: Peter Kreiner
  • Prescription Drug Monitoring Program Data Analysis and Evaluation Assistance, 2017-2018
    Brandeis Lead Scientist: Peter Kreiner
  • Prescription Drug Monitoring Program Data Analysis and Evaluation Assistance, 2018-2019
    Brandeis Lead Scientist: Gail Strickler
  • Massachusetts’ Prescription Drug Monitoring Program: The goals are to maximize the capabilities of law enforcement officials to identify individuals involved in illicit prescription drug activity, develop enhancements to the online Massachusetts Prescription Awareness Tool (MassPAT) and improve the quality of prescription information
    Brandeis Lead Scientist: Gail Strickler

Resources/Technical Assistance

  • Brandeis Opioid Research Clearing House (BORC): The Opioid Resource Connector assists communities in mounting a comprehensive response to the opioid crisis.
    Brandeis Lead Scientist: Cindy Parks Thomas

Publications

2021

2020

2019

  • Meunch U, Perloff J, Thomas CP. Opioid prescribing outcomes of Medicare beneficiaries managed by nurse practitioners and physicians. Medical Care 2019; 57(6):482-489.
  • Thomas CP. Commentary:  Addressing workforce needs for medication treatment for opioid use disorder.  Journal of Addiction Medicine 2019; 13(1):1–2. doi: 10.1097/ADM.0000000000000442
  • Adams RS, Thomas CP, Ritter GA, et al. Predictors of post deployment opioid receipt and long-term prescription opioid utilization among army active duty soldiers.   Military Medicine 2019; 2019 Jan 1;184(1-2):e101-e109. PMCID: PMC6329665
  • Adams, R.S., Corrigan, J.D., and Dams-O’Connor, K. “Risk for Opioid Use Disorder Among Individuals with Traumatic Brain Injury.” Presented at 2019 Addiction Health Services Research Conference, Park City, Utah, October 2019.

  • Hodgkin, D, Garnick, DW, Horgan, CM, Busch, AB, Stewart, MT, Reif, S. (2019). Is it feasible to pay specialty substance use disorder treatment programs based on patient outcomes? Drug and Alcohol Dependence, 206 107735.

  • Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. (2019). The Washington state hub and spoke model to increase access to medication treatment for opioid use disorders. Journal of Substance Abuse Treatment, 108 33-39.

  • Davis MT, Torres M, Nguyen A, Stewart MT, Reif S. (2019). Improving quality and performance in substance use treatment programs: What is being done and why is it so hard? Journal of Social Work.

  • Mazel, S., Hennig, S., Zisman-Ilani, Y., and Nicholson, J. “Exploring Mothers’ Perceptions of Substance Use and Substance Use Treatment.” Presented at 2019 Addiction Health Services

  • Adams, R.S., Dietrich, E.J., Gray, J.C., Milliken, C.S., Moresco, N., and Larson, M.J. (2019). “Post-Deployment Screening in the Military Health System: An Opportunity to Intervene for Possible Alcohol Use Disorder.” Health Affairs. 38(8), pp. 1298-1306.

  • Nicholson, J., de Girolamo, G., and Schrank, B. (2020). Editorial. “Parents With Mental and/or Substance Use Disorders and Their Children.” Frontiers in Psychiatry. Published online Dec. 10, 2019.

2018

  • Acevedo A, Miles J, Garnick DW, Panas L, Ritter G, Campbell K, Acevedo-Garcia D. "Employment after beginning treatment for substance use disorders: The impact of race/ethnicity and client community of residence." Journal of Substance Abuse Treatment. 87, (2018): 31-41. doi: 10.1016/j.jsat.2018.01.006
  • Weiner, SG, Baker, O, Rogers, AF, Garner, C, Nelson, LS, Kreiner, PW, and Schuur, JD. (2018). Opioid prescriptions by specialty in Ohio, 2010-2014. Pain Medicin, 19(5): 978-989. doi: 10.1093/pm/pnx027
  • Young, L, Kreiner, PW, Panas, L. (2018) Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison GroupPain Medicine, 19(7):1396-1407.
  • Kolodny A, Frieden TR. (2018) Government Actions to Curb the Opioid Epidemic—Reply. JAMA, 17;319(15):1620-1621. doi: 10.1001/jama.2018.0745.
  • Acevedo A, Miles J, Garnick DW, Panas L, Ritter G, Campbell K, Acevedo-Garcia D. (2018). Employment after beginning treatment for substance use disorders: The impact of race/ethnicity and client community of residence. Journal of Substance Abuse Treatment. 87, 31-41. PMCID: PMC5830150
  • Lee MT, Acevedo A, Garnick DW, Horgan CM, Panas L, Ritter GA, Campbell K. (2018). Impact of agency incentives and reminders on engagement and care continuity for clients with co-occurring disorders. Psychiatric Services. 69(7):804-811. PMCID: PMC6193487

2017

Prior to 2017

  • Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. (2016) Primary Care Physicians' Knowledge and Attitudes Regarding Prescription Opioid Abuse and Diversion. Clin J Pain, 32(4):279-84. doi: 10.1097/AJP.0000000000000268.
  • Kolodny A. (2016) Chronic Pain Patients Are Not Immune to Opioid Harms. J Pain Palliat Care Pharmacother, 30(4):330-331.  DOI:10.1080/15360288.2016.1231736 
  • Harris, AHS, Weisner, CM, Chalk, M, Capoccia, V, Chen, C, Thomas, CP. Specifying and Pilot Testing Quality Measures for the American Society of Addiction Medicine’s Standards of Care. Journal of Addiction Medicin 2016;. May/June 10(3): 148-155.
  • Thomas CP, Hodgkin D, Levit K, Mark Growth in spending on substance use disorder treatment services for the privately insured population. Drug and Alcohol Dependence 2016 Mar 1;160:143-50.
  • Mark T, Levit K, Hodgkin D, Thomas CP. Growth in use of treatment services for mental and substance use disorders under private insurance after the great recessio Psychiatric Services 2016 May 1;67(5):504-9.
  • Hodgkin D, Thomas CP, O’Brien M, Levit K, Richardson J, Mark TL, Malone Projected spending on psychotropic medicines, 2013-1020. Administration and Policy in Mental Health and Mental Health Services Research 2016; Jul;43(4):497-505.
  • Kolodny, A, Courtwright, DT, Hwang, CS, Kreiner, PW, Eadie, JL, Clark, TW, Alexander, GC. (2015) The prescription opioid and heroin crisis: a public health approach to an epidemic of addictionAnnu Rev Public Health, 36:559-574.
  • Ballantyne JC, Kolodny A. (2015) Preventing prescription opioid abuse (letter). JAMA. Mar 10;313(10):1059.

  • Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. (2015) Prescription Drug Abuse: A National Survey of Primary Care Physicians. JAMA Intern Med. Feb;175(2):302-4.

  • Paulozzi LJ, Strickler GK, Kreiner P, Koris CM (2015).  Controlled substance prescribing patterns—Prescription Behavior Surveillance System, eight states, 2013. MMWR Surveillance Summary, Oct 16;64(9), 1-14. doi: 10.15585/mmwr.ss6409a1.
  • Acevedo A, Garnick DW, Dunigan R, Horgan CM, Ritter G, Lee MT, Panas L, Bidorini, A., Campbell, K., Haberlin, K., Lambert-Wacey, D., Leeper, T., Reynolds, M., Wright, D. (2015)  Performance Measures and Racial/Ethnic Disparities in the Treatment of Substance Use Disorders. Journal of Studies on Alcohol and Drugs. 76: 57-67. PMCID: PMC4263781  

  • Thomas, C.P., Kim, M.L., Nikitin, R., Carrow, G.M., Clark, T., Kreiner, P. “Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts.” Pharmacoepidemiology and Drug Safety 23(9). (2014):950-970, doi: 10.1002/pds.3666

  • Fullerton, C.A., Kim, M.L.; Thomas, C.P.; Lyman, D.R., Montejano, L.B., Dougherty, R.H., Daniels, A.S., Ghose, S.S., Delphin-Rittmon, M.E. “Medication-Assisted Treatment with Methadone: Assessing the Evidence.” Psychiatric Services 65(2). (2014): 146-157. doi:10.1176/appi.ps.201300235.
  • Thomas, C.P., Fullerton, C.A., Kim, M.L., Montejano, L., Lyman, D.R., Dougherty, R.H., Daniels, A.S., Ghose, S.S., Delphin-Rittmon, M.E. “Medication-Assisted Treatment with Buprenorphine: Assessing the Evidence.” Psychiatric Services 65(2). (2014): 158-170. doi:10.1176/appi.ps.201300256.
  • Thomas CP, Kim M, Nikitin R, Kreiner P, Clark T, Carrow GM. Prescriber response to unsolicited prescription monitoring reports in Massachusett Pharmacoepidemiology and Drug Safety 2014;23(9):950-957.
  • O’Brien PM, Thomas CP, Hodkin D, Levit K, Mark TL. The diminished pipeline for medications to treat mental health and substance use disorder Psychiatric Services 2014; 65(12):1433-1438.
  • Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon M Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services 2014; 65(4):146-157.
  • Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano L, Dougherty RH, Daniels AS, Ghose SS, Delphin-ritten M Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services 2014; 65(4):158-170.
  • Garnick DW, Horgan CM, Acevedo A, Lee MT, Panas L, Ritter G, Dunigan R, Bidorini A, Campbell K, Haberlin K, Huber A, Lambert-Wacey D, Leeper T, Reynolds M, Wright D. (2014). Criminal justice outcomes after engagement in outpatient substance abuse treatment. Journal of Substance Abuse Treatment. 46: 295-305. PMCID: PMC3947052
  • Lee MT, Horgan CM, Garnick DW,  Acevedo A, Panas L, Ritter G, Dunigan R, Babakhanlou-Chase H, Bidorini A, Campbell K, Haberlin K, Huber A, Lambert-Wacey D, Leeper T, Reynolds M. (2014) A performance measure for continuity of care after detoxification: Relationship with outcomes. Journal of Substance Abuse Treatment. 47(2): 130-139. PMCID: PMC4076006

  • Dunigan R, Acevedo A, Campbell K, Garnick DW, Horgan CM, Huber A, Lee MT, Panas L, Ritter G. (2014). Engagement in outpatient substance abuse treatment and employment outcomes. Journal of Behavioral Health Services & Research. 41: 20-36. PMCID: PMC3796147
  • Thomas, C., Kim, M.L., Kelleher, S., Nikitin, R., Kreiner, P., McDonald, A., & Carrow, G.  “Early experience with electronic prescribing of controlled substances in a community setting.” Journal of the American Medical Informatics Association (e1). (2013): e44-51. doi: 10.1136/amiajnl-2012-001499.
  • Kolodny A. (2013) Better late than never: time to up-schedule hydrocodone combination products. Pain Medicine. 11:1627-1628.
  • Thomas CP, Kim M, Kelleher SJ, Nikitin RV, McDonald A, Carrow GM. Early experience with electronic prescribing of controlled substances in a community setting.  Journal of the American Medical Informatics Association 2013 Jun;20(e1):e44-51.
  • Thomas CP, Garnick DW, Horgan C, Miller K, Harris AG, Rosen MM. Establishing the feasibility of measuring performance in use of addiction pharmacotherapy, Journal of Substance Abuse Treatment 2013 Jul;45(1):11
  • Ryan, M., Merrick, E. L., Hodgkin, D., Horgan, C.M., Garnick, D.W., Panas, L., Ritter, G., Blow, F., Saitz, R. (2013), Drinking Patterns of Older Adults with Chronic Medical Conditions.  Journal of General Internal Medicine. doi: 10.1007/s11606-013-2409.l

  • Thomas C.P., Kim, M.L., McDonald A., Kreiner, P., Kelleher Jr, S.J., Blackman, M., Kaufman, P.N. Carrow, G.M. “Prescribers’ expectations and barriers to electronic prescribing of controlled substances.” Journal of the American Medical Informatics Association 19(3). (2012): 375-381. doi:10.1136/amiajnl-2011-000209.
  • Ballantyne J, Sullivan M, Kolodny A. (2012) Opioid Dependence vs Addiction—A Distinction Without a Difference? Arch Intern Med. 1 72(17):1342-1343.
  • Shepard DS, Zeng W, Strickler GK, Lwin AK, Cros MJ, Garner BR (2012).  The Brief Treatment Cost Analysis Tool (TCAT-Lite) for substance abuse treatment: Reliability and application.  Alcoholism Treatment Quarterly, 30(4), 377-396.

  • Strickler GK, Reif S, Horgan, CM, Acevedo A. (2012).  The relationship between substance abuse performance measures and mutual help group participation after treatment. Alcoholism Treatment Quarterly, 30(2), 190-210.

  • Strickler GK, Reif S, Merrick EL, Horgan CM, Hiatt D. (2012). Substance abuse treatment preferences in an employed population.  Journal of Workplace Behavioral Health, 27, 117-125.

  • Thomas CP, Kim M, McDonald A, et Prescribers’ expectations and barriers to electronic prescribing of controlled substances. Journal of the American Medical Informatics Association (2012);19:375-381.
  • Lee, MT, Garnick, DW, O'Brien, PL, Panas, L, Ritter, GA, Acevedo, A, Garner, BR, Funk, RR, Godley, MD. "Adolescent treatment initiation and engagement in an evidence-based practice initiative." Journal of Substance Abuse Treatment 42. 4 (2012): 346-355.

  • Garnick, DW, Lee, MT, O'Brien, ML, Panas, L, Ritter, GA, Acevedo, A, Garner, BR, Funk, RR, Godley, MD. "The Washington Circle Engagement Performance Measures' Association with Adolescent Treatment Outcomes." Drug and Alcohol Dependence. 124. (2012): 250-258.

  •  Acevedo, A., Garnick, D.W., Lee, M.T., Horgan, C.M., Ritter, G., Panas, L., Davis, S., Leeper, T., Moore, R., Reynolds, M. (2012) "Racial/Ethnic Differences in Substance Abuse Treatment Initiation and Engagement." Journal of Ethnicity in Substance Abuse 11. 1-21.

  • Von Korff M, Kolodny A, Deyo R, Chou R. (2011) Long-Term Opioid Therapy Reconsidered. Annals of Internal Medicine. 155-325-328.
  • Thomas CP, Garnick DW, Horgan CM et Advancing performance measures for use of medications in substance abuse treatment. Journal of Substance Abuse Treatment 2011 Jan;40(1):35-43.
  • Merrick, E. L., Hodgkin, D., Panas, L., Soumerai, S. B. and Ritter, G. (2011), Is customization in antidepressant prescribing associated with acute-phase treatment adherence? Journal of Pharmaceutical Health Services Research. doi: 10.1111/j.1759-8893.2011.00068. x.

  • Merrick E, Hodgkin D, Garnick D, Horgan C, Panas L, Ryan M, Saitz R, Blow F. (2011) Older Adults’ Inpatient and Emergency Department Utilization for Ambulatory-Care-Sensitive Conditions: Relationship with Alcohol Consumption, Journal of Aging and Health. 2011 Jan;23(1):86-111.

  • Katz N, Panas L, Kim M, Audet A, Bilansky A, Eadie J, Kreiner P, Paillard F, Thomas CP. Usefulness of Prescription Monitoring programs for Surveillance – Analysis of Schedule II Opioid Prescription Data in Massachusetts, 1996-2006. Pharmacoepidemiology and Drug Safety,  19. 2 (2010): 115-23.
  • Katz, N., Panas, L., Kim, ML, Audet, AD, Bilansky, A, Eadie, J, Kreiner, P, Paillard, FC, Thomas, C, Carrow, G. "Usefulness of prescription monitoring programs for surveillance - analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006," Pharmacoepidemiology and Drug Safety 19(2). (2009): 115-123.
  • Bishop CE, Ryan A, Gilden DM, Kubisiak J, Thomas CP. Effect of an Expenditure Cap on Low-income Seniors' Drug Use and Spending in a State Pharmacy Assistance Program. Health Services Research, June 2009, 44:3;1010.
  • Katz N, Panas L, Kim M, Audet A, Bilansky A, Eadie J, Kreiner P, Paillard F, Thomas C, Carrow G. (2009) Usefulness of Prescription Monitoring Programs for Surveillance – Analysis of Schedule II Opiod Prescription Data in Massachusetts, 1996-2006, Pharmacoepidemiology and Drug Safety. 2009 Dec; 19(2):115-123.

  • Katz N, Houle B, Fernandez KC, Kreiner P, Thomas CP, Kim ML, Carrow GM, Audet A, Brushwood D. "Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators." Pain Medicine 9(5). (2008): 587-594.
  • Wallack SS, Thomas CP, Chilingerian J, Reif S, Martin T. Substance Abuse Treatment Organizations as Mediators of Social Policy: Slowing the Adoption of a Congressionally Approved Medication. TheJournal of Behavioral Health Services & Research July 2008,10.1007/s11414-008-9132-4.
  • Thomas CP, Reif S, Haq S, Wallack SS, Hoyt A, Ritter GA. “Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and other psychiatrists.” Psychiatric Services 2008;59(8):909-916.
  • Hodgkin D, Thomas CP, Ritter GA, Lee S, Simoni-Wastila L. Effect of a three tier formulary on antidepressant use and expenditure  Journal of Mental Health Policy and Economics 2008;11(2):68-78.
  • Thomas CP, Hodgkin D, Ritter GA, Martin T, Wallack SS. “Trends in mental health and substance abuse presecription drug spending: Lessons from an era of high spending growth.”  Journal of Pharmaceutical Finance,Economics and Policy, 2008 16(3):67-84.
  • Harrison M, Lednyak L, Kolodny A, Petit J. (2008) Buprenorphine: an office-based treatment for opioid dependence. City Health Information. 27(4):25–32. 
  • Merrick E, Horgan C, Hodgkin D, Garnick D, Houghton S, Panas L, Saitz R, Blow F. (2007) Unhealthy Drinking Patterns in Older Adults: Prevalence and Associated Characteristics, Journal of the American Geriatrics Society. 2008 Feb;56(2):214-23.

  • Magura S, Lee S, Salsitz E, Kolodny A, Whitley S, Taubes T, Seewald R, Joseph H, Kayman D, Fong C, Marsch L, Rosenblum A. (2007) Outcomes of Buprenorphine Maintenance in Office- based Practice. Journal of Addictive Disorders. 26(2):13-23.
  • Kolodny A. (2007) Psychiatrists as Administrators: The Perspective of a Mental Health Department Psychiatrist. Psychiatric Quarterly. April 14.
  • Reif, Sharon; Thomas, CP; Wallack Stanley S. "Factors determining how early adopter physicians use buprenorphine in treatment" Journal of Addiction Medicine 2007 1(4): 205-2
  • Wallack SS, Thomas CP, Martin T. “Differences in Prescription Drug management between HMOs and Self insured health plans,” Medical Care Research and Review 2007;64(1):98-11
  • Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependenc Journal of Substance Abuse Treatment 2007; 32(2):207-215.
  • Garnick D, Horgan C, Lee M, Panas L, Ritter G, Davis S, Leeper T, Morre R, Reynolds M. (2007) Are Washington Circle performance measures associated with decreased criminal activity following treatment? Journal of Substance Abuse Treatment. 2007 De  c;33(4):341-352. PMCID: PMC2692984

  • Thomas CP, Conrad P, Casler R, and Goodman E. “Trends in prescribing of psychotropic medications to adolescents, 1996-2001.” Psychiatric Services 2006; 57(1):63
  • Kolodny A. (2006) Psychiatric consequences of methamphetamine use. Journal of GLBT Psychotherapy. 10:67-72.
  • Wainberg M, Kolodny A, Drescher J. Crystal meth and MSM: What mental health care professionals need to know. Binghamton, NY: Haworth Press,
  • Kolodny A, Sederer L. (2005) Brief interventions for alcohol problems. City Health Information. 24(8): 51-58.
  • Shepard DS, Strickler GK, McAuliffe WE, Beaston-Blaakman A, Rahman, M, Anderson TE (2005).  Unmet need for substance abuse treatment of adults in Massachusetts.  Administration and Policy in Mental Health, 32(4), 403-426.

  • Thomas CP, Wallack SS, and Martin TA, “How do seniors use their prescription drug discount cards?” Health Affairs web exclusive, 19 April 2005 (www.healthorg).
  • Hodgkin D, Shepard DS, Anthony YE, Strickler GK (2004).  A publicly managed Medicaid substance abuse carve-out: Effects on spending and utilization.  Administration and Policy in Mental Health, 31(3), 197-217.

  • Simoni-Wastila L, Ritter G, Strickler G (2004). Gender and other factors associated with the non-medical use of abusable prescription drugs.  Substance Use and Misuse, 39(1), 1-23.

  • Simoni-Wastila L, Strickler G (2004). Risk factors associated with problem use of prescription drugs. American Journal of Public Health, 94(2), 266-268.

  • Sederer LI, Kolodny AJ. (2004) Taking issue: Office based buprenorphine offers a second chance. Psychiatric Services. 55:743.

  • Sederer LI, Kolodny AJ. (2004) Detecting and treating depression in adults. City Health Information. 23(1):1-8.
  •  Kolodny A, Lamon S, Sederer L. (2004) Buprenorphine: A new office-based treatment for opioid dependence. City Health Information. 23(4): 19-22.
  • Wainberg M, Kolodny A, Siever L. Personality Disorders. In: Preskorn SH, Feighner JP, Stanga CY & Ross R, eds., Antidepressants: Past, Present and Future. Springer Verlag, Berlin, Germany, 2004: 489-515.
  • Wallack SS, Weinberg DB, and Thomas CP. “Health plans’ strategies to control prescription drug spending.” Health Affairs  2004;23(6):141-1
  • Harris K and Thomas CP. “Naltrexone and pharmacy benefit management.” Journal of AddictiveDiseases 2004;23(4):11-
  • Thomas CP and McCarty D. Book chapter: “Adoption of substance abuse treatment medications in primary care” in Institute of Medicine, New Medications for Addictions, National Academies Press, Jun 3, 2004.
  • Thomas CP, Wallack SS, Lee S, McCarty D, and Swift R. “Research to Practice: Adoption of Naltrexone by Clinical Providers,” Journal of Substance Abuse Treatment, 2003; 24(2):1-11.
  • Thomas CP, Wallack SS, Lee S, and Ritter GA. “Impact of Plan Design and Management on Retirees’ Prescription Drug Use and Expenditures” Health Affairs Web Exclusive, December 4, 2002.
  • Altman S and Thomas CP. “Editorial: Controlling Prescription Drug Expenditures” New England Journal of Medicine 2002; 346(11):855-85
  • Thomas CP and Wallack, SS. “Economic Factors in Adoption of New Alcoholism TreatmentMedications.”  The Economics of Neuroscience 2001;3(12):52-57.
  • Thomas CP, Ritter G, and Wallack SS. Growth in Prescription Drug Spending Among Insured Elde Health Affairs 2001; 20(5) (September/October):265-277.
  • Thomas CP and Ritter Drug Utilization Trends by Therapeutic Class. Web publication for the Department of Health and Human Services Office of Health Policy, August, 2000. (www.aspe.hhs.gov/health/reports/Drug-papers/thomas/thomas-final.htm).
  • Min P, Kolodny A. The Middleman Minority Characteristics of Korean Immigrants in the United States. In: Kim K, ed. Koreans in the Hood: Conflict with African Baltimore: Johns Hopkins University Press, 1999: 131-154.